Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies

Bibliography

• Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406(6797):782-7
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2(8):675-80
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85(2):85-95
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216
   PubMed Web of Science ®Google Scholar
• Park BS, Song DH, Kim HM, The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458(7242):1191-5
   PubMed Web of Science ®Google Scholar
• Golenbock DT, Leggett JE, Rasmussen P, Lipid X protects mice against fatal Escherichia coli infection. Infect Immun 1988;56(4):779-84
   PubMed Web of Science ®Google Scholar
• Golenbock DT, Will JA, Raetz CR, Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin. Infect Immun 1987;55(10):2471-6
   PubMed Web of Science ®Google Scholar
• Andersson U, Wang H, Palmblad K, High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192(4):565-70
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Lowry SF, Cerami A. Cachectin/TNF mediates the pathophysiological effects of bacterial endotoxin/lipopolysaccharide (LPS). Prog Clin Biol Res 1988;272:77-88
   Google Scholar
• Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm 2010;2010:568396
   PubMed Web of Science ®Google Scholar
• Rice TW, Wheeler AP, Bernard GR, A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010;38(8):1685-94
   PubMed Web of Science ®Google Scholar
• Roger T, Froidevaux C, Le Roy D, Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci USA 2009;106(7):2348-52
   PubMed Web of Science ®Google Scholar
• Rietschel ET, Kirikae T, Schade FU, Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994;8(2):217-25
   PubMed Web of Science ®Google Scholar
• Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 2001;7(3):167-202
   PubMedGoogle Scholar
• Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004;4(11):1147-71
   PubMed Web of Science ®Google Scholar
• Mullarkey M, Rose JR, Bristol J, Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003;304(3):1093-102
   PubMed Web of Science ®Google Scholar
• Savov JD, Brass DM, Lawson BL, Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2005;289(2):L329-37
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Tsujimoto T, Kawaratani H, Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol 2010;25(5):1009-12
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Tsujimoto T, Kawaratani H, Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol 2009;24(6):1089-94
   PubMed Web of Science ®Google Scholar
• Sun Y, Pearlman E. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). Invest Ophthalmol Vis Sci 2009;50(3):1247-54
   PubMed Web of Science ®Google Scholar
• Shimamoto A, Chong AJ, Yada M, Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006;114(1 Suppl):I270-4
   PubMedGoogle Scholar
• Liu M, Gu M, Xu D, Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc 2010;42(5):1539-44
   PubMed Web of Science ®Google Scholar
• Ondiveeran HK, Fox-Robichaud A. Drug evaluation: E-5564. IDrugs 2004;7(6):582-90
   PubMedGoogle Scholar
• Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002;8(6):483-8
   PubMedGoogle Scholar
• Kim HM, Park BS, Kim JI, Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007;130(5):906-17
   PubMed Web of Science ®Google Scholar
• Visintin A, Halmen KA, Latz E, Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005;175(10):6465-72
   PubMed Web of Science ®Google Scholar
• Wong YN, Rossignol D, Rose JR, Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003;43(7):735-42
   PubMed Web of Science ®Google Scholar
• Rossignol DP, Wong N, Noveck R, Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. Innate Immun 2008;14(6):383-94
   PubMed Web of Science ®Google Scholar
• Rossignol DP, Wasan KM, Choo E, Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 2004;48(9):3233-40
   PubMed Web of Science ®Google Scholar
• Wasan KM, Sivak O, Cote RA, Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations. Antimicrob Agents Chemother 2003;47(9):2796-803
   PubMed Web of Science ®Google Scholar
• Kaneko K, Ueda R, Kawata T, LPS binding protein does not participate in the pharmacokinetics of E5564. J Endotoxin Res 2004;10(3):185-94
   PubMedGoogle Scholar
• Kaneko K, Ueda R, Nemoto H, Disposition of a synthetic analogue of lipid A (E5564) in rats. Xenobiotica 2003;33(3):323-39
   PubMed Web of Science ®Google Scholar
• Wasan KM, Risovic V, Sivak O, Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits. Pharm Res 2008;25(1):176-82
   PubMed Web of Science ®Google Scholar
• Liang E, Wong YN, Allen I, Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function. J Clin Pharmacol 2003;43(12):1361-9
   PubMed Web of Science ®Google Scholar
• Solomon SB, Cui X, Gerstenberger E, Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis 2006;193(5):634-44
   PubMed Web of Science ®Google Scholar
• Lynn M, Rossignol DP, Wheeler JL, Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003;187(4):631-9
   PubMed Web of Science ®Google Scholar
• Lynn M, Wong YN, Wheeler JL, Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]. J Pharmacol Exp Ther 2004;308(1):175-81
   PubMed Web of Science ®Google Scholar
• Bennett-Guerrero E, Grocott HP, Levy JH, A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2007;104(2):378-83
   PubMed Web of Science ®Google Scholar
• Tidswell M, Tillis W, Larosa SP, Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010;38(1):72-83
   PubMed Web of Science ®Google Scholar
• Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000;9(7):1651-63
   PubMed Web of Science ®Google Scholar
• Opal SM, Scannon PJ, Vincent JL, Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180(5):1584-9
   PubMed Web of Science ®Google Scholar
• Sweeney DA, Danner RL, Eichacker PQ, Once is not enough: clinical trials in sepsis. Intensive Care Med 2008;34(11):1955-60
   PubMed Web of Science ®Google Scholar
• Manocha S, Feinstein D, Kumar A. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 2002;11(12):1795-812
   PubMed Web of Science ®Google Scholar
• Angus DC, Birmingham MC, Balk RA, E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000;283(13):1723-30
   PubMed Web of Science ®Google Scholar
• Bone RC, Balk RA, Fein AM, A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995;23(6):994-1006
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Wilson KM, Kunz AY, Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, gram-negative sepsis. Crit Care Med 1992;20(6):730-5
   PubMed Web of Science ®Google Scholar
• Harkonen S, Scannon P, Mischak RP, Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother 1988;32(5):710-16
   PubMed Web of Science ®Google Scholar
• Reinhart K, Gluck T, Ligtenberg J, CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004;32(5):1100-8
   PubMed Web of Science ®Google Scholar
• Panacek EA, Marshall JC, Albertson TE, Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32(11):2173-82
   PubMed Web of Science ®Google Scholar
• Abraham E, Glauser MP, Butler T, p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277(19):1531-8
   PubMed Web of Science ®Google Scholar
• Fisher CJ Jr, Dhainaut JF, Opal SM, Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271(23):1836-43
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fisher CJ Jr, Sprung CL, Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324(7):429-36
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garg R, Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353(13):1332-41
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-709
   PubMed Web of Science ®Google Scholar
• Eichacker PQ, Parent C, Kalil A, Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002;166(9):1197-205
   PubMed Web of Science ®Google Scholar
• Minneci PC, Deans KJ, Eichacker PQ, The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009;15(4):308-18
   PubMed Web of Science ®Google Scholar
• Barochia AV, Cui X, Natanson C, Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis. Crit Care Med 2010;38(1):306-8
   PubMed Web of Science ®Google Scholar
• Wong HR, Cvijanovich N, Lin R, Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009;7:34
   PubMed Web of Science ®Google Scholar
• Opal SM, Scannon PJ, Vincent JL, Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180(5):1584-9
   PubMed Web of Science ®Google Scholar
• Agnese DM, Calvano JE, Hahm SJ, Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186(10):1522-5
   PubMed Web of Science ®Google Scholar
• Child NJ, Yang IA, Pulletz MC, Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003;31(Pt 3):652-3
   PubMedGoogle Scholar
• Poltorak A, He X, Smirnova I, Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282(5396):2085-8
   PubMed Web of Science ®Google Scholar
• Kaneko K, Ueda R, Kikuchi K, Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1999;736(1-2):67-75
   PubMedGoogle Scholar
• Zhou Z, Kozlowski J, Schuster DP. Physiologic, biochemical, and imaging characterization of acute lung injury in mice. Am J Respir Crit Care Med 2005;172(3):344-51
   PubMed Web of Science ®Google Scholar
• Ma CX, Yin WN, Cai BW, Activation of TLR4/NF-kappaB signaling pathway in early brain injury after subarachnoid hemorrhage. Neurol Res 2009. [Epub ahead of print]
   Google Scholar
• Rossignol DP, Lynn M. TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs 2005;6(5):496-502
   PubMedGoogle Scholar
• Suganuma A, Rossignol DP, Kaneko K, Clinical pharmacology of E5564, a lipid A antagonist, in a canine lipopolysaccharide challenge model. J Endotoxin Res 2000;6:115
   Google Scholar